Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 A standardized plaque reduction assay for determination of drug susceptibilities of cytomegalovirus clinical isolates.

Literature DB >> 10681339

A standardized plaque reduction assay for determination of drug susceptibilities of cytomegalovirus clinical isolates.

M L Landry¹, S Stanat, K Biron, D Brambilla, W Britt, J Jokela, S Chou, W L Drew, A Erice, B Gilliam, N Lurain, J Manischewitz, R Miner, M Nokta, P Reichelderfer, S Spector, A Weinberg, B Yen-Lieberman, C Crumpacker.

Abstract

Twelve laboratories collaborated in formulating and testing a standardized plaque reduction assay for cytomegalovirus (CMV) cell-associated clinical isolates. Four characterized and plaque-purified CMV strains, as well as six coded clinical isolates obtained after antiviral therapy, were distributed and tested. Good agreement was obtained for four of the clinical isolates, but a broad distribution of results was obtained for two isolates. Analysis of these results indicates the problems associated with clinical isolates, including the large genetic variability and the highly cell-associated phenotype. This collaborative effort, by addressing these problems, represents a significant step toward the development of a standardized assay.

Mesh：

Substances：

Year: 2000 PMID： 10681339 PMCID： PMC89747 DOI： 10.1128/AAC.44.3.688-692.2000

Source DB: PubMed Journal: Antimicrob Agents Chemother ISSN： 0066-4804 Impact factor: 5.191

12 in total

1. Foscarnet therapy for ganciclovir-resistant cytomegalovirus retinitis in patients with AIDS.

Authors: M A Jacobson; W L Drew; J Feinberg; J J O'Donnell; P V Whitmore; R D Miner; D Parenti
Journal: J Infect Dis Date: 1991-06 Impact factor: 5.226

2. Prevalence of resistance in patients receiving ganciclovir for serious cytomegalovirus infection.

Authors: W L Drew; R C Miner; D F Busch; S E Follansbee; J Gullett; S G Mehalko; S M Gordon; W F Owen; T R Matthews; W C Buhles
Journal: J Infect Dis Date: 1991-04 Impact factor: 5.226

3. Progressive disease due to ganciclovir-resistant cytomegalovirus in immunocompromised patients.

Authors: A Erice; S Chou; K K Biron; S C Stanat; H H Balfour; M C Jordan
Journal: N Engl J Med Date: 1989-02-02 Impact factor: 91.245

4. Ganciclovir-resistant cytomegalovirus clinical isolates: mode of resistance to ganciclovir.

Authors: S C Stanat; J E Reardon; A Erice; M C Jordan; W L Drew; K K Biron
Journal: Antimicrob Agents Chemother Date: 1991-11 Impact factor: 5.191

5. Plaque assay of cytomegalovirus strains of human origin.

Authors: B B Wentworth; L French
Journal: Proc Soc Exp Biol Med Date: 1970-11

6. Novel mutation in the UL97 gene of a clinical cytomegalovirus strain conferring resistance to ganciclovir.

Authors: M N Hanson; L C Preheim; S Chou; C L Talarico; K K Biron; A Erice
Journal: Antimicrob Agents Chemother Date: 1995-05 Impact factor: 5.191

7. Analysis of the UL97 phosphotransferase coding sequence in clinical cytomegalovirus isolates and identification of mutations conferring ganciclovir resistance.

Authors: S Chou; A Erice; M C Jordan; G M Vercellotti; K R Michels; C L Talarico; S C Stanat; K K Biron
Journal: J Infect Dis Date: 1995-03 Impact factor: 5.226

8. Antiviral susceptibilities and analysis of UL97 and DNA polymerase sequences of clinical cytomegalovirus isolates from immunocompromised patients.

Authors: A Erice; C Gil-Roda; J L Pérez; H H Balfour; K J Sannerud; M N Hanson; G Boivin; S Chou
Journal: J Infect Dis Date: 1997-05 Impact factor: 5.226

9. Monitoring of ganciclovir sensitivity of multiple human cytomegalovirus strains coinfecting blood of an AIDS patient by an immediate-early antigen plaque assay.

Authors: G Gerna; F Baldanti; M Zavattoni; A Sarasini; E Percivalle; M G Revello
Journal: Antiviral Res Date: 1992-10-01 Impact factor: 5.970

10. A protein kinase homologue controls phosphorylation of ganciclovir in human cytomegalovirus-infected cells.

Authors: V Sullivan; C L Talarico; S C Stanat; M Davis; D M Coen; K K Biron
Journal: Nature Date: 1992-07-09 Impact factor: 49.962

36 in total

1. Role of the laboratory in diagnosis and management of cytomegalovirus infection in hematopoietic stem cell and solid-organ transplant recipients.

Authors: Raymund R Razonable; Carlos V Paya; Thomas F Smith
Journal: J Clin Microbiol Date: 2002-03 Impact factor: 5.948

Review 2. Human cytomegalovirus resistance to antiviral drugs.

Authors: C Gilbert; G Boivin
Journal: Antimicrob Agents Chemother Date: 2005-03 Impact factor: 5.191

3. Phenotyping of cytomegalovirus drug resistance mutations by using recombinant viruses incorporating a reporter gene.

Authors: Sunwen Chou; Laura C Van Wechel; Heather M Lichy; Gail I Marousek
Journal: Antimicrob Agents Chemother Date: 2005-07 Impact factor: 5.191

4. Novel real-time monitoring system for human cytomegalovirus-infected cells in vitro that uses a green fluorescent protein-PML-expressing cell line.

Authors: T Ueno; Y Eizuru; H Katano; T Kurata; T Sata; S Irie; K Ogawa-Goto
Journal: Antimicrob Agents Chemother Date: 2006-08 Impact factor: 5.191

5. Use of time-saving flow cytometry for rapid determination of resistance of human cytomegalovirus to ganciclovir.

Authors: Gyu-Cheol Lee; Dong-Gun Lee; Su-Mi Choi; Jin-Hong Yoo; Sun-Hee Park; Jung-Hyun Choi; Woo-Sung Min; Ok-Hee Cho; Chan-Hee Lee; Wan-Shik Shin
Journal: J Clin Microbiol Date: 2005-10 Impact factor: 5.948

6. New reporter cell line to evaluate the sequential emergence of multiple human cytomegalovirus mutations during in vitro drug exposure.

Authors: C Gilbert; G Boivin
Journal: Antimicrob Agents Chemother Date: 2005-12 Impact factor: 5.191

7. Recombinant phenotyping of cytomegalovirus UL54 mutations that emerged during cell passages in the presence of either ganciclovir or foscarnet.

Authors: Christian Gilbert; Arezki Azzi; Nathalie Goyette; Sheng-Xiang Lin; Guy Boivin
Journal: Antimicrob Agents Chemother Date: 2011-06-27 Impact factor: 5.191